Genprex, INC 8-K filings

Genprex, Inc. stockholders approved key proposals at their 2025 Annual Meeting, including an expanded equity incentive plan, a potential reverse stock split, and a significant stock issuance to Lincoln Park Capital Fund, LLC.

Genprex, Inc. provides a corporate update detailing significant progress in its oncology and diabetes gene therapy programs, including ongoing clinical trials and preclinical advancements.

Genprex, Inc. announced positive preclinical research results for its diabetes gene therapy drug candidate, GPX-002, demonstrating transdifferentiation of alpha cells to insulin-secreting beta-like cells and improved glucose control in animal models.

Genprex, Inc. announced positive preclinical data for its diabetes gene therapy drug candidate, GPX-002, utilizing a novel non-viral lipid nanoparticle delivery system, presented at the 2025 American Diabetes Association 85th Scientific Sessions.

Genprex, Inc. has entered into a purchase agreement with Lincoln Park Capital Fund, LLC for up to $12.5 million in common stock, alongside updates on its Acclaim-1 and Acclaim-3 lung cancer clinical trials, both of which have received FDA Fast Track Designation.

Genprex, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement but continues to face a delisting threat due to its common stock trading below the $1.00 minimum bid price.

Genprex, Inc. has entered into a new Sponsored Research Agreement with the University of Pittsburgh to further study GPX-002, its gene therapy for Type 1 and Type 2 diabetes, following promising preclinical results.

Genprex has obtained an exclusive patent license from UTHealth Houston for its Reqorsa Gene Therapy, targeting the treatment of glioblastoma.

Genprex, Inc. has secured an exclusive patent license agreement with NYU Langone Health for its Reqorsa Gene Therapy, a potential treatment for mesothelioma, enhancing its oncology portfolio.

Genprex strengthens its diabetes program with an updated license agreement and the creation of Convergen Biotech, Inc., a wholly-owned subsidiary dedicated to diabetes gene therapy development.

Genprex, Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing, adding to existing concerns about stockholders' equity.

Genprex has dosed the first patient in the Phase 2 expansion of its Acclaim-3 clinical trial, evaluating Reqorsa gene therapy with Tecentriq for advanced small cell lung cancer.

Genprex, Inc. has released an investor presentation detailing updates on its oncology clinical trials and diabetes gene therapy program.

Genprex's Acclaim-3 clinical trial for Reqorsa gene therapy in combination with Tecentriq has completed its Phase 1 dose escalation, with the Safety Review Committee approving the start of Phase 2 expansion.

Genprex has obtained an exclusive worldwide license from the University of Michigan for its Reqorsa gene therapy in combination with ALK inhibitors, targeting ALK-positive lung cancer.

Genprex, Inc. received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement for continued listing, placing its stock at risk of delisting.

Genprex, Inc. has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing.

Genprex has entered into a sponsored research agreement with the University of Michigan Rogel Cancer Center to study its lead drug candidate, Reqorsa, in combination with ALK-inhibitors for ALK-positive lung cancer.

Genprex's Acclaim-3 clinical trial for Reqorsa gene therapy in combination with Tecentriq has successfully completed the 0.09 mg/kg dose group and is approved to escalate to the highest dose group of 0.12 mg/kg.

Genprex, Inc. has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

Genprex plans to transfer its diabetes clinical development program and assets into a new, wholly-owned subsidiary to focus on its diabetes gene therapy candidate, GPX-002.

Genprex has been granted a patent in Singapore for its Reqorsa gene therapy in combination with anti-PD-1 antibodies, expanding its global intellectual property portfolio.

Genprex announced a corporate update detailing progress in its clinical programs for cancer and diabetes, including the enrollment of patients in new lung cancer trials and expansion of preclinical programs.

Genprex has amended its executive employment agreement with Ryan M. Confer, settled a separation agreement with Catherine Vaczy, and updated its outside director compensation policy.

Genprex, Inc. reports the unexpected death of its CEO, Rodney Varner, and the immediate appointment of Ryan Confer as the new President and CEO.

Genprex, Inc. has entered into agreements for a $6.5 million registered direct offering of common stock and warrants, priced at-the-market under Nasdaq rules.

Genprex's research collaborators will present positive preclinical data on Reqorsa and NPRL2 gene therapies for lung cancer at the upcoming AACR 2024 Annual Meeting.

Genprex, Inc. has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement, resolving a previous non-compliance issue.

Genprex has dosed the first patient in the Phase 2a expansion of its Acclaim-1 clinical trial for lung cancer, while also announcing the departure of a key executive and providing an update on the CEO's health.

Genprex Inc. has received notice of resignation from executive officer Catherine Vaczy, with discussions ongoing regarding her departure.